Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.

Pfizer

Status and phase: Completed; Phase 2

Conditions: Colorectal Neoplasms

Treatments: Drug: SU011248

Study type: Interventional

Funder types: Industry

Identifiers

NCT00077987

A6181003

Details and patient eligibility

About

Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Metastatic colorectal cancer
• Failed selected cancer therapies in the past.

Exclusion criteria

• Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than bevacizumab.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)